Log in

NASDAQ:AFMDAffimed Stock Price, Forecast & News

$3.48
+0.17 (+5.14 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.27
Now: $3.48
$3.60
50-Day Range
$1.98
MA: $2.52
$3.45
52-Week Range
$1.42
Now: $3.48
$3.74
Volume1.42 million shs
Average Volume1.47 million shs
Market Capitalization$265.32 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More
Affimed logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.96 million
Book Value$0.57 per share

Profitability

Net Income$-36,250,000.00
Net Margins-149.51%

Miscellaneous

Employees8,406
Market Cap$265.32 million
Next Earnings Date6/10/2020 (Estimated)
OptionableOptionable

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

Affimed (NASDAQ:AFMD) Frequently Asked Questions

How has Affimed's stock been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AFMD shares have increased by 91.2% and is now trading at $3.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Affimed?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Affimed.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for Affimed.

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) released its quarterly earnings data on Tuesday, April, 28th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company had revenue of $4.35 million for the quarter. Affimed had a negative net margin of 149.51% and a negative return on equity of 93.90%. View Affimed's earnings history.

What price target have analysts set for AFMD?

2 brokers have issued twelve-month price targets for Affimed's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Affimed's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 187.4% from the stock's current price. View analysts' price targets for Affimed.

Has Affimed been receiving favorable news coverage?

News articles about AFMD stock have trended somewhat negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Affimed earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAffimed.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.85%), Stonepine Capital Management LLC (3.93%), Wellington Management Group LLP (3.76%), State Street Corp (1.56%), AQR Capital Management LLC (1.44%) and Geode Capital Management LLC (0.83%).

Which institutional investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Stonepine Capital Management LLC, Telemetry Investments L.L.C., UBS Group AG, BlackRock Inc., Geode Capital Management LLC, Alpine Global Management LLC, and Invesco Ltd..

Which institutional investors are buying Affimed stock?

AFMD stock was purchased by a variety of institutional investors in the last quarter, including Los Angeles Capital Management & Equity Research Inc., State Street Corp, Jane Street Group LLC, AQR Capital Management LLC, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Lindbrook Capital LLC, and Parametric Portfolio Associates LLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $3.48.

How big of a company is Affimed?

Affimed has a market capitalization of $265.32 million and generates $23.96 million in revenue each year. The biopharmaceutical company earns $-36,250,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Affimed employs 8,406 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.